App-Quantinova.ai

CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS

A. Rubbert-Roth - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS

I. Mcinnes - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

guselkumab (IV)

CONSTRUCT VALIDITY, RELIABILITY, RESPONSIVENESS AND INTERVAL SCALE TRANSFORMATION OF THE WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX (WOMAC) IN PATIENTS UNDERGOING KNEE ARTHROPLASTY

Y. Y. Leung - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (lcSSc) AND INTERSTITIAL LUNG DISEASE (ILD)

Y. Allanore - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

Nintedanib

CONTROL OF RHEUMATIC DISEASE AND COVID-19: RESULTS FROM THE INTERNATIONAL COVID-19 EUROPEAN PATIENT REGISTRY

S. Shoop-Worrall - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

CORRELATION OF SKIN SCORES (LoSCAT) WITH PATIENT REPORTED OUTCOMES IN JUVENILE LOCALISED SCLERODERMA

C. Pain - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

COULD THE RENIN-ANGIOTENSIN SYSTEM AFFECT THE PROGNOSIS OF GIANT CELL ARTERITIS? SINGLE-CENTRE RETROSPECTIVE OBSERVATIONAL STUDY

R. Venkateswaran - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Angiotensin II

COVID-19 ADMISSIONS AND MORTALITY IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIS: RESULTS FROM A NATIONAL COHORT

M. Adas - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Early inflammatory arthritis

N/A

COVID-19 HAD AN ADVERSE IMPACT ON DENOSUMAB TREATMENT PROVISION - COMPARISON WITH PRE-PANDEMIC WAITING TIMES AT A UK-BASED RHEUMATOLOGY DEPARTMENT

S. Ling - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Denosumab

COVID-19 INFECTION AND RECOVERY AMONGST PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR)

S. Dyball - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Coronavirus disease

N/A

COVID-19 OUTCOMES IN PATIENTS WITH DERMATOMYOSITIS: A REGISTRY-BASED COHORT ANALYSIS

L. Gupta - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lung injury

Glucocorticoid

COVID-19 PREVENTION IN PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR)

S. Dyball - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Coronavirus disease

N/A

COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.

L. Gupta - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY

P. Sen - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

COVID-19, INFLUENZA AND PNEUMOCOCCUS VACCINATION UPTAKE IN PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE AUDIT

R. Mazumder - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Influenza

N/A

CREATION OF A MULTI-DISCIPLINARY TEAM (MDT) RHEUMATOLOGY CLINIC AT UNIVERSITY COLLEGE LONDON HOSPITAL (UCLH) TO TACKLE THE BACKLOG OF PATIENTS WAITING FOR TREATMENT AS A RESULT OF THE COVID-19 PANDEMIC.

D. Ludwig - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

CYCLING OF JAK-INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SINGLE-CENTRE EXPERIENCE

C. Vassallo - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

ABT-494

DAS28 (DISEASE ACTIVITY SCORE) ELEVATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO HAVE COMORBID FIBROMYALGIA ARE EXPLAINED BY ELEVATED TENDER JOINT COUNTS AS MUCH AS BY ELEVATED PATIENT GLOBAL ASSESSMENT

S. Kannayiram - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

DE-ESCALATION OF DMARDs IN ELDERLY PATIENTS WITH RA

L. Robson - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

DEFINING DISTINCT RESIDENT AND MIGRATORY FIBROBLAST POPULATIONS FROM SKIN BIOPSIES IN SYSTEMIC SCLEROSIS

K. Clark - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Collagenase

Filters

45280 Abstracts